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ABSTRACT
In this review, a summary of our current
understanding of squamous cell carcinoma of
the anus (SCCA) and the advances in our
knowledge of SCCA regarding screening,
prevention, the role of the immune system,
current treatment and the potential for novel
targets are discussed. The present standard of
care in terms of treatment is 5-fluorouracil
(5-FU) and mitomycin C (MMC) concurrently
with radiation, which results in a high level of
disease control for small early cancers.
Preservation of the anal sphincter is achieved
in the majority, although anorectal function is
often impaired. Although evidence from
prospective studies to support a change in the
treatment strategy is lacking, patients with
HPV-negative SCCA appear to be less
responsive to chemoradiation (CRT) and
relapse more frequently. In contrast,
HPV-positive tumours usually fare better, but
oncological outcomes are modified by smoking
and immune incompetence. There is current
interest in escalating the radiotherapy dose for
larger, more advanced tumours, and
de-escalating treatment for HPV-positive
tumours. The use of novel immunological
treatments to target the underlying different
molecular pathways of HPV-positive cancers is
exciting.




Radiotherapy; Squamous cell carcinoma of the
anus
INTRODUCTION
Squamous cell carcinoma of the anus (SCCA) is
a rare malignancy which accounts for only
2–4% of all lower alimentary tract
malignancies [1]. The incidence of SCCA has
been rising and is now approximately 1.8 per
100,000, accounting for[7000 men and
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women per year in the US. Data from Public
Health England show that the incidence of
SCCA increased 126% in women and 69% in
men in the UK during the period 1990–1994 to
2006–2010 [2].
Due to its rarity, few high-quality
randomised controlled trials are available to
guide our decision-making. SCCA generally
presents as a localised disease with a low risk
of metastatic disease unless CRT fails.
Locoregional failure is the predominant
pattern of relapse [3] and is responsible for
most SCCA–related deaths, making local
control (LC) the primary aim of treatment and
the primary endpoint in some trials.
Overall survival (OS) has usually been a
secondary endpoint in the trials. OS may not,
however, be the most useful endpoint because
OS requires large numbers of patients for
sufficient events (such large numbers of
patients with rare cancers are even more
difficult to recruit), and there are competing
risks of death in an elderly population. Also, the
availability and feasibility of subsequent
effective and specialist surgical salvage have
not been uniform. These observations partly
explain why the overall 5-year survival appears
very similar in trials: 78% in the MMC arm of
the Radiotherapy Therapy Oncology Group
RTOG 98-11 trial [4], 71% in the CRT-alone
arms of the Action Clinique Coordonne´es en
cance´rologie Digestive (ACCORD-03) [5] and
79% in the MMC arm of the Anal Cancer Trial
(ACT II) [6]. Preservation of the anal sphincter is
achieved in the majority, although with doses
of 50–60 Gy (as used in the phase III trials),
anorectal function is often impaired [7]. The
outcomes for patients with larger cT3/T4
cancers are less favourable. In the RTOG 98-11
trial, patients with cT2/T3N0 had a 5-year
disease-free survival (DFS) of 70%, which fell
to 38% for cT3N1-3 and only 31% for cT4N1-3
[8]. In ACT II, patients with cT3/T4 cancers and/
or nodal metastases had a 3-year
progression-free survival (PFS) of 63% [6] (see
Table 1).
The randomised trials involving SCCA
patients examined three cytotoxic agents as
radiotherapy partners (5-fluorouracil,
mitomycin C and cisplatin). Although the
schedules are similarly timed (often days 1–5
and days 29–33), the number of doses and the
total mg delivered in these regimens have not
been consistent (Table 2). CRT using 5-FU and
MMC, which has been tested in several
randomised trials [6, 9–12], is the standard of
care which results in a high level of disease
control for cT1/T2 cancers and is currently
recommended in European and US guidelines
[13, 14].
Although there is a clear need for more
effective treatments in more advanced cT3/T4
and/or node-positive cancers, additional
strategies examined in trials have so far failed
to improve outcomes, in part because the CRT
component was not always optimised.
Randomised phase III trials by the RTOG 98-11
[12], the ACCORD-03 phase III trial [5] and the
ACT II trial failed to show any additional benefit
in terms of PFS by increasing the radiotherapy
boost dose, or replacing MMC with cisplatin
during CRT [6]. Nor has additional
cisplatin-based chemotherapy given as
induction prior to CRT [5, 12] or as
maintenance chemotherapy after CRT [6]
improved outcomes.
There have been some intriguing
developments in the past 3 years in terms of
our understanding of the molecular biology and
processes which lead to SCCA, and the vital role
of the immune system. There have also been
some notable successes in prevention, imaging
(e.g. MRI for staging delineation and restaging)
and treatment. This paper will discuss these
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advances, but limit its discussion to SCC arising
in the anal canal and margin, and ignore other
biologically distinct anal tumours such as
melanomas, neuroendocrine tumours,
adenocarcinomas, lymphomas and GIST
tumours.
This article is based on previously conducted
studies and does not involve any new studies of




The incidence of SCCA has been increasing
over the past three decades—most markedly in
women. The natural history is usually slow,
with patients complaining of symptoms for
months if not years, and distant metastases
are uncommon at presentation [10, 15, 16].
Hence, SCCA is usually amenable to
locoregional CRT, which is a potentially
curative treatment.
Risk Factors and Aetiology
The role of human papillomavirus (HPV) in the
aetiology of SCCA was described more than
20 years ago [17]. SCCA is associated with HPV
in 80–90% of cases [18, 19] (usually in Europe
HPV16 or HPV18 subtypes), as is the precursor
high-grade anal–intraepithelial neoplasm (AIN).
Women with previous HPV-related cervical,
vulvar or vaginal diseases are at a higher risk
of developing SCCA.
A 30-fold higher risk of SCCA is observed in
human immunodeficiency virus (HIV)-infected
patients compared to the general population
[20]. Other recognised risk factors for the
development of SCCA include the long-term
use of immunosuppressants such as
azathioprine and corticosteroids, and
autoimmune disorders such as systemic lupus.
Transplant recipients have a tenfold risk
compared to the general population. Social
deprivation is implicated [21]. A history of
receptive anal intercourse increases the risk,
but is not a necessary condition. Cigarette
smoking is a potent risk factor [22, 23].
Cigarette smoking may also have a role in the
persistence of HPV infection, and potentially
influences outcomes from treatment. Even in
the context of HIV, patients with SCCA who
smoke also appear to have a worse overall
survival than nonsmoking patients [24].
Although previously discounted, recent data
also suggest that there is a higher incidence of
SCCA in Crohn’s disease, an earlier age of
presentation and poorer outcomes [25]. There
is no clear association with any dietary habits or
the presence of haemorrhoids [26, 27]. Men
who have sex with men (MSM) have a high
incidence of SCCA:(35 per 100,000, which
increases to 75–135 per 100,000 with HIV
seropositivity. The incidence is also higher
among HIV-seropositive women [28].
Substantial evidence implicates HPV in the
aetiology of SCCA. HPV has been identified in
84.5% of cases in a meta-analysis examining
HPV prevalence in AIN and SCCA from 93
studies conducted in four different continents
[18]. HPV16 and HPV18 appear to be the two
commonest genotypes detected. Prospective
data also link HPV seropositivity to the risk of
subsequent SCCA [29]. HIV-positive and
HIV-negative homosexual men are more likely
than the general population to be infected with
HPV, often with more than one subtype [30],
and are more likely to demonstrate
HPV-associated AIN.
HPV is virtually endemic, with a lifetime risk
of acquiring genital HPV at least once of[80%
[31]. HPV infects squamous cells at the deep
aspect of the perianal skin or anorectal mucosa
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by way of ulceration or trauma to the superficial
layers. HPV overrides the cell’s normal
machinery and DNA synthesis, replicating
itself and releasing further HPV into the
surrounding epithelium. Individuals infected
with HPV are asymptomatic and hence
unaware of the infection. Most of those
infected will clear the virus within 2 years,
without harm to the host. Factors which
contribute to the delayed clearance of anal
HPV in women include douching, cigarette
smoking, and performing anal sex [32], but
there are no recognised interventions to treat
active HPV infection. Anal intercourse and a
high lifetime number of sexual partners
increase the risk of persistent HPV infection in
men and women. It is unknown why virus
persistence and chronic infection, which later
lead to HPV-induced SCCA, develop in a few
patients. Not all persistent infections cause
disease. Our impression is that patients with
HPV-associated SCCA tend to present, on
average, a decade younger than patients with
HPV-negative cancer.
HPV-positive cell lines appear intrinsically
more radiosensitive, with clear differences in
cell cycle check-point and apoptotic signalling
pathways, as well as reduced DNA repair
abilities. This finding may be partly explained
by the association of HPV with the viral
proteins E6 and E7, which integrate into the
host DNA [33] and inhibit normal antiviral
immune mechanisms but are insufficient on
their own for malignancy. E6 and E7 inhibit the
activity of the tumour-suppressor proteins p53
(in the host) and pRb (in normal cells) [34],
creating aberrant apoptosis as a first step to
allowing cells to become immortal. The E7
protein binds and inactivates the
retinoblastoma (Rb) protein. The role of Rb is
to regulate E2F (a transcription factor
controlling cell cycle progression). Inactivation
of Rb releases the brakes from E2F (see Fig. 1), so
cell cycle progression is unchecked via the
Fig. 1 Illustrating the relationship of HPV E6 and E7 and the cell cycle
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activation of p16, a cyclin-dependent kinase
inhibitor that functions as a check-point
inhibitor.
p16INK4A (p16)
p16 (also known as cyclin-dependent kinase
inhibitor 2A) is a tumor-suppressor protein.
Positive immunohistochemical staining (IHCS)
for p16 is used as a surrogate for HPV
involvement, based on the high concordance
between these two biomarkers. However, p16
IHC analysis cannot distinguish between
HPV-16, the most common HPV genotype
found in squamous cell carcinoma of the head
and neck (SCCHN), and other rarer and more
aggressive genotypes. However, better
responsiveness to radiation does not wholly
explain the improved outcomes, as HPV?/p16?
SCCHN cases treated with surgery alone appear
to demonstrate improved RFS and OS [35].
Anal Intraepithelial Neoplasia
SCCA may arise from a precursor dysplastic
lesion—anal intraepithelial neoplasia (AIN)—
also known as anal squamous intraepithelial
lesions (SILs). The concept of intraepithelial
pre-cancer was first described in the context of
cervical cancer in 1888 by Sir John Thomas.
There is an ongoing debate arguing that the
traditional three-tiered grading of AIN1, AIN2
and AIN3 should be replaced by a more
reproducible two-tiered system (effectively
high grade versus low grade). AIN I is
considered a low-grade squamous
intraepithelial lesion (LSIL or LGAIN). AIN 2
and 3 are rated as a high-grade squamous
intraepithelial lesion (HSIL or HGAIN). HSIL or
HGAIN/AIN3 is increasingly being identified
during the screening of immunosuppressed
patients for anal dysplasia, but the prevalence
of AIN in the general population is low [36]. It
may approach 20% in HIV?men [37], and even
higher in MSMs. Progression from AIN to
invasive malignancy is uncommon in
immunocompetent patients [38] but more
frequent in immunosuppressed patients [39]
and older patients. Progression is also
influenced by HIV seropositivity, a low CD4
count and the serotype of HPV infection
[40, 41]. These groups have a high risk of
high-grade AIN and more rapid progression to
invasive cancer [42].
The natural history of progression from AIN
to invasive carcinoma in HIV-positive
individuals has changed with effective
treatment using highly active antiretroviral
therapy (HAART). HIV-positive individuals can
expect to live longer and thus have longer
exposure with their immune suppression to the
effects of HPV. Hence, SCCA is the commonest
malignancy in HIV-positive individuals in the
United States [43].
PREVENTION
Prevention can be divided into primary and
secondary. Primary prevention aims to prevent
HPV infection persisting long-term. Secondary
prevention relies on methods of identifying
pre-cancerous lesions (AIN) or very early stage
cancers with appropriate definitive treatment.
Two available vaccines—a bivalent HPV 16/18
vaccine (Cervarix) and a quadrivalent HPV 6/11/
16/18 vaccine (Gardasil)—have been used in the
prevention of cervical, vaginal and vulvar warts/
AIN/early cancer. There is now also a 9-valent
vaccine (Gardasil 9) in use [44]. The HPV types
detected in SCCA are included in the 9-valent
vaccine, so it should in future effectively prevent
SCCA if administered to boys and girls prior to
the onset of sexual activity.
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HPV Vaccination
Safe and effective vaccines against HPV-16 and
HPV-18 infection have been commercially
available for a decade. Since most SCCA and
pre-cancerous lesions are attributed to human
papillomavirus (HPV) infection, prevention of
HPV infection reduces the risk of SCCA/AIN.
Vaccination against HPV-16 and HPV-18 has
been shown to be highly effective in preventing
cervical dysplasia and thus cervical cancer [45].
Recently, the quadrivalent HPV vaccine
(effective against the four most common HPV
types: 6, 11, 16 and 18) has also been shown to
be highly effective in preventing HPV-16 and
HPV-18 associated anal dysplasia [46]. This
double-blind study reported a reduction in the
rates of AIN in healthy MSM of 54.2% (95% CI
18.0–75.3) in the intention-to-treat population
and 74.9% (95% CI 8.8–95.4) in the
per-protocol efficacy population [46]. A large
proportion of SCCA cases could theoretically be
prevented in the future.
However, there is a question regarding the
durability of the protection. One study in MSM
with treated high-grade AIN who received the
quadrivalent HPV vaccine reported a
significantly reduced risk of recurrence
compared with those who did not receive the
vaccine, which appears to be durable for at least
2 years. However, 12/88 vaccinated MSM
(13.6%) still developed a recurrence, so it is
not 100% effective in this population. The
antibody response may attenuate over time
[47]. In women, the duration may be more
prolonged [48].
Although HPV vaccines may prevent future
HPV infection, they do not eliminate existing
high-risk HPV infections or treat patients who
already have SCCA. The efficacy of the two
available vaccines against oncogenic HPV is
more than 90% for both cervical and anal
intraepithelial neoplasia. However, there is no
HPV vaccination programme for boys in the
UK. Spillover via herd immunity may offer
some protection to males, but it is anticipated
that incidence rates may rise in men—
particularly men who have sex with men
(MSM)—because of this policy. Therapeutic
vaccines targeting the E6/E7 oncogenes or the
cellular pathways which they drive might do so
[49]. A study using a vaccine against the HPV-16
oncoproteins E6 and E7 has reported clinical
responses in women with HPV-16-positive, G3
vulvar intraepithelial neoplasia [50]. However,
these agents may also indirectly improve
natural immunity.
In summary, HPV vaccination of girls and
boys in early adolescence might be expected to
prevent SCCA in the general population and
among future cohorts of persons infected with
HIV/MSM, but prophylactic vaccines are
unlikely to affect people already infected with
HIV and exposed to oncogenic HPV. However,
it also remains unclear how long the immune
response will continue to give protection.
Screening
SCCA is rare in the general population, but
similarities in both the epidemiology and
aetiology between squamous cancers of the
cervix and the anus have raised the suggestion
that similar screening programmes in
appropriate high-risk groups could reduce the
incidence of SCCA. Anal cytology and
high-resolution anoscopy (HRA) in
asymptomatic patients are feasible and are
currently performed in many clinics in the
USA [51, 52], although practices vary widely.
Any identified internal high-grade AIN can be
treated with infrared coagulation, and external
high-grade AIN with excision, imiquimod or
topical 5-fluorouracil (although recurrence is
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not uncommon in immunocompromised
populations where HPV infection tends to
persist). In HIV-positive patients,
electrocautery appears more effective than
imiquimod or topical fluorouracil in the
treatment of AIN, but recurrence rates were
again substantial [53].
However, we are not aware of mature data
from any long-term controlled trials to evaluate
screening for SCCA. Hence, the optimal
methods of screening remain under debate.
The value of screening for SCCA using anal
cytology [54] or high-resolution anoscopy [55]
is currently being investigated, mainly in
groups with major risk factors such as MSM,
patients with HIV, HIV- women with a history
of anal intercourse or other HPV-related
anogenital malignancies, and patients
immunosuppressed as a result of solid-organ
transplantation, but it remains rarely performed
by general surgeons [56]. The hypothesis of
benefit is based on the favourable results
obtained in cervical cytology (Pap smear)
screening. These tests may detect dysplasia
before it develops into invasive cancer and
pre-cancerous lesions (AIN). Yet, because it is
unusual for AIN/HSIL to progress to cancer even
without treatment, the specificity of anal
cytological screening may be too low.
HPV16 E6 seropositivity is relatively
common some years before the diagnosis of
SCCA, and could be used as a screening tool. In
a recent study of patients with anogenital
cancers, HPV16 E6 seropositivity was present
in plasma in 7/24 individuals (29.2%) 3–8 years
before they developed SCCA compared with
0.6% of controls (4/718) who remained
cancer-free [57]. More specific targets, such as
high-risk HPV genotypes’ DNA or RNA or E6
seropositivity, may be a more effective
component of future screening programmes.
But, as we have already remarked above, no
randomised control study has yet demonstrated
the advantage of screening in these high-risk
populations, and we are currently not aware of
any national programmes involved in
widespread screening via Pap smear testing for
SCCA.
Finally the frequency of further surveillance,
once AIN is identified, remains controversial.
Some recommend a clinical review every
12 months in HIV-negative patients with
low-grade AIN, and increasing the frequency
to 4–6 months in HIV-infected or patients with
high-grade AIN [41]. Others use clinical and
cytological screening every 3 months in
patients with high-grade AIN [58].
PRESENTATION AND DIAGNOSIS
Presentation
A mean age between 60 and 70 years is reported
in European studies [10, 11, 59, 60], but is
typically a decade younger in studies from the
USA [12, 61, 62], which partly reflects the
inclusion/noninclusion of patients with HIV.
One of the commonest presenting symptoms
in SCCA is rectal bleeding, which can delay
diagnosis because bleeding is often attributed to
haemorrhoids. The saying ‘‘nearly every lesion
around the anus is liable to be called ‘piles’ by
the patient and not infrequently by the
referring doctor also’’ remains relevant [63].
Other common presenting symptoms include
pain, anal discharge, an unpleasant fishy odour,
pruritus ani and ulceration. Once the anal
sphincters are involved, patients complain of
soiling and then frank faecal incontinence with
occasional fistula formation. Often the patient
is aware of a lump. Occasionally patients
present with enlarged inguinal lymph nodes in
the absence of anal symptoms.
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Anatomy and Lymphatic Drainage
The anal canal is approximately 3–5 cm in
length, depending on the sex of the patient. It
starts inferiorly at the anal verge representing
the lowermost edge of the sphincter muscles.
The anal margin extends from this anal verge
and is considered the perianal skin with a 5 cm
radius. The most proximal (i.e. superior) portion
of the anal canal drains to perirectal nodes in
the mesorectum and nodes along the superior
rectal vessels to the inferior mesenteric system,
and thereon to the paraaortic nodes, with
additional drainage to the internal iliac and
obturator nodes.
In tumours arising above the dentate line,
drainage is via internal pudendal nodes to the
internal iliac system. The upper half of the canal
drains mainly by the superior rectal vein to the
inferior mesenteric vein, while the lower half
drains via the inferior rectal vein. Hence,
metastases may occur either to the liver via
the portal system or the lung via the systemic
circulation, depending on the height of the
tumour. Below the dentate line, drainage is to
the superficial inguinal nodes, femoral nodes
and external iliac nodes. The most frequent sites
for nodal metastases are inguinal, femoral and
iliac lymph nodes [64]. Clinically palpable
(inguinal) lymph nodes are found in 16–25%
of cases [12, 59, 65]. Fewer than 5% have distant
metastases at presentation [10, 59, 62].
Histopathology
Histological confirmation is mandatory prior to
treatment, as other histological entities are
possible in the anal canal. The biopsy
specimen should be assessed to document the
size of the tumour in terms of the greatest
dimension in mm in all possible planes, and to
comment on the resection margins at depth
and at the periphery to decide if further
treatment is required, particularly for tumours
excised at the anal margin, which behave more
like skin cancers. However, this may prove
impossible if a piecemeal resection has been
performed.
In the past, high-grade tumours were
expected to be associated with a worse
prognosis, but multivariate analysis in the
randomised trials has not confirmed this view.
Tumours of the anal margin are usually well
differentiated and seen in men, but canal
tumours are often poorly differentiated and
more common in women; however, many
view histological grading as subject to
considerable interobserver variability and to be
of limited prognostic value [66]. There is also
heterogeneity observed in larger tumours.
Histological subclassifications of basaloid,
transitional, spheroidal and cloacogenic cell
cancers no longer influence management [13],
although some authors retrospectively report
that a basaloid histological subtype confers a
higher risk of developing metastatic disease
[67]. Verrucous carcinoma represents a further
variant, which is sometimes described as a giant
condyloma or Buschke–Lowenstein tumour.
Prognostic Factors
Recognised prognostic factors for SCCA are
based on standard clinical and biological
features, consisting mainly of TNM stage, site
of disease, performance status, comorbidities,
smoking history and molecular markers such as
HPV/p16 status (see below). The clinical factors
elicited from the randomised trials are
summarised in Table 3. However, even when
patients are categorised according to these
parameters, there are still considerable
differences in behaviour, response and
outcome. In future, advances in molecular
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biology and genomic technologies may allow
the identification of different genomic and
epigenomic patterns developing during
tumour progression, and offer greater
individualisation in the choice of treatment.
Molecular Biomarkers
A prognostic biomarker informs regarding the
overall outcome for the patient, irrespective of
the treatment to be given. In contrast, a
predictive biomarker informs regarding the
likely effect of a specific therapeutic
intervention. Analysis of molecular differences
between a large number of tumour specimens
could identify such biomarkers, allowing the
tailoring of treatment to individual patients and
possibly the identification of new therapeutic
targets.
Prognostic Biomarkers
Squamous cell carcinoma antigen (SCCAg) is a
serum tumour marker expressed by SCCA which
correlates with initial tumour stage and/or
nodal status [68]. We have found this marker
to be useful in complementing the initial
staging and target delineation for
radiotherapy, but its clinical utility in
diagnosis, prognosis and follow-up remains
controversial [69].
In an attempt to distinguish the relative risk
of anal exposure to human papillomavirus
(HPV) infection, immunodeficiency, and
combined antiretroviral therapy in the
development of SCCA in HIV-positive men (in
particular MSM), a case-control study examined
various factors, including the prevalence of HPV
E6 antibodies [70]. Current smoking, prior low
CD4? count and antibodies to E6 were
significantly associated with SCCA. However,
HPV E6, although very specific, is a relatively
insensitive biomarker for SCCA.
The most comprehensive review of
molecular markers examined different
biomarkers belonging to nine functional
classes: tumour suppressors, epidermal growth
factor receptors (EGFR), apoptosis regulation,
proliferation index, angiogenesis,
tumour-specific markers (e.g. SCCAg and
CEA), Hedgehog signalling, and telomerase
[71]. The tumour-suppressor genes p53 and
p21 were the only biomarkers demonstrating
prognostic value in more than one study.
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Overexpression of p53 is common in anal
carcinomas [72, 73] and helps to regulate the
cell cycle and apoptosis. Inactivation of p53
leads to dysregulation of key cellular events
[73] and may result from either mutations in
its gene or sequestration by other cellular
proteins, such as the E6 viral oncoprotein of
the HPV virus [74]. In an unpublished analysis
using samples collected from 240 patients
randomised within the UKCCCR ACT I SCCA
trial [10], the presence of mutated p53
predicted a poorer cause-specific survival in
both arms [75].
Predictive Biomarkers
In a small study of 30 patients treated with CRT,
examination of biomarkers related to
chemotherapy and/or radiation resistance
suggested on multivariate analysis that Ki67,
nuclear factor kappa B, sonic hedgehog, and
nuclear Gli-1 are potentially associated with
DFS [76].
A recent report explored potential
biomarkers with the aim of identifying novel
treatment strategies [77]. SCCA specimens were
tested via a multiplatform profiling service
consisting of gene sequencing, protein
expression by immunohistochemistry (IHC)
and gene amplification (by CISH or FISH). This
study demonstrated frequent expression of
resistance-conferring proteins, i.e. multi-drug
resistance-associated protein 1 (MRP1); excision
repair cross-complementing gene 1 (ERCC1),
which confers resistance to platinum-based
chemotherapy; and thymidylate synthase (TS),
which has a role in fluoropyrimidine resistance
[77]. In contrast, the same study identified a




Cell cycle progression is unchecked via the
activation of p16, a cyclin-dependent kinase
inhibitor that functions as a checkpoint
inhibitor. IHC for p16 has been used as a
surrogate for HPV involvement. The analysis
of HPV-DNA by either polymerase chain
reaction or p16 expression can be used as an
independent prognostic marker for both OS and
DFS in patients with SCCA [78–80].
p16 expression is associated with greater
radiosensitivity in the tumour and possibly
with favourable inflammatory responses,
although other factors such as smoking
modify the better oncological outcomes
associated with p16?. However, using p16
expression as a predictive biomarker requires
prospective validation in a clinical trial prior to
entering routine use (or being used to stratify
treatments in future trials).
In contrast, there is increasing recognition
that patients with p16-negative SCCA, although
uncommon [81], often fail to respond toCRT [79]
and generally have worse outcomes following
CRT. Relapse-free rates in p16- cases are worse
than in p16? cases [78, 79, 82–84]. Rates of p16
positivity range from65% [83] to 93% [78], so the
majority of relapses still occur in p16-positive
patients. The more favourable prognosis for
p16? partly reflects intact apoptotic machinery
in the cell and low rates of p53mutation [71, 79],
whichmaintains the response to CRT. The above
information suggests that differentmanagement
strategies/regimens are probably required for
tumours which are p16 negative and thereby
more difficult to control with standard CRT
schedules.
In oropharyngeal cancers, a high circulating
neutrophil count is associated with an inferior
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RFS and poor OS, but this effect seems to be
limited to patients with p16-positive cancers
[85]. In a small retrospective study of 92
patients with SCCA, an elevated
neutrophil:lymphocyte ratio (NLR) was
associated with worse overall (p\0.0001) and
cancer-specific (p\0.0001) survival [86].
Tumour-infiltrating lymphocyte scores can
also be used to stratify p16? cases even further
in terms of the risk of relapse [87]. Hence, in
HPV?/p16? SCCA, both the systemic (NLR)
and the local inflammatory environment, such
as tumour-infiltrating lymphocytes (TILs), may
influence clinical outcomes.
Staging and Initial Assessment
Staging information is useful for determining
prognosis but also informs the clinician on the
optimal management (i.e. systemic or local) and
the choice of treatments. The information is
also required by the radiation oncologist to
delineate gross tumour volume (GTV) and
contour the appropriate nodal and elective
volumes. The risk of recurrence may also
determine the most appropriate radiotherapy
dose and the intensity of follow-up. The unified
American Joint Committee on Cancer/
International Union Against Cancer (AJCC/
UICC) staging system incorporates primary
tumour size (T), lymph node status (N) and
distant metastases (M). The 7th edition of the
AJCC/UICC classification for SCCA is shown in
Table 4 [88].
The recommended staging procedures are
shown in Table 5 stage by stage. Assessment of
each patient with SCCA should specifically
include palpation of the groins for the
presence of inguinal lymphadenopathy—
particularly the superficial inguinal nodes, and
those medial and close to the pubis—but
radiological assessment with/without fine
needle aspirate cytology may also be helpful.
Digital rectal examination (DRE) is required to
assess the primary tumour and any perirectal/
mesorectal nodal involvement. A vaginal
examination is important in women
(particularly with anteriorly placed tumours)
to determine the site and size of the primary
tumour, vaginal/vaginal septal involvement,
mucosal involvement and exophytic or
ulcerative tumour, or the presence of a fistula.
Examination under anaesthesia (EUA) can
facilitate accurate clinical staging. Precise
tumour measurements and topography need
to be documented, as these are often critical for
later target volume delineation in radiotherapy
treatment planning.
In the UK, magnetic resonance imaging
(MRI) of the pelvis is the staging modality of
choice, because it provides excellent clarity
regarding the primary tumour with
multiplanar anatomical detail, and highlights
the involvement of surrounding structures [89].
Pelvic MRI also offers more information on
nodal involvement, particularly in the
mesorectum and inguinal regions, than
clinical staging with CT, which is crucial for
accurate radiotherapy planning. Distant
metastases are assessed with computed
tomography (CT) of the thorax and abdomen.
Transrectal ultrasound (TRUS) may be better
than MRI in detecting small superficial
tumours. TRUS allows a 360 view of the anal
canal and can accurately assess the depth of
tumor infiltration and involvement of the
sphincter mechanism and fistula tracts. TRUS,
however, is poor at assessing lymph node
involvement in the mesorectum and pelvis.
Finally, the majority of anal carcinomas are
FDG-avid. PET/CTwith [18F]fluorodeoxyglucose
(FDG-PET/CT) has a high sensitivity in
identifying involved lymph nodes, and a high
specificity in immunocompetent patients.
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Hence, FDG-PET/CT can provide information on
primary tumour size and lymph node status and
can image distant metastases, but lymph nodes
below 8 mm in size are unlikely to show uptake,
even if involved. A study from Mount Vernon
suggests that PET/CT can diagnose distant
Table 4 Seventh edition of the AJCC/UICC TNM staging for anal canal cancer
Primary tumour (T)
Tx Primary tumour cannot be assessed
Tis Carcinoma in situ [Bowens disease, high-grade intraepithelial lesion (HSIL),
anal intraepithelial neoplasia (AIN) II–III]
T1 Tumour less than 2 cm in greatest dimension
T2 Tumour between 2 and 5 cm in greatest dimension
T3 Tumour more than 5 cm in greatest dimension
T4 Tumour invading adjacent organs [vagina, urethra, bladder, sacrum]
Regional lymph nodes (N)
NX Regional nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in perirectal nodes
N2 Metastasis in unilateral internal iliac and/or inguinal nodes
N3 Metastasis in perirectal and/or bilateral internal iliac or inguinal nodes
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Anatomic stage/prognostic groups
0 Tis N0 M0
I T1 N0 M0
II T2 N0 M0
T3 N0 M0




IIIB T4 N1 M0
Any T N2 M0
Any T N3 M0
IV Any T Any N M1
AJCC Cancer Staging Manual, 7th edition (2010)
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metastatic disease that CT scan fails to detect,
and alters staging in 42%of patients [90]. PET/CT
also has utility in radiation therapy treatment
planning as it facilitates the delineation of
metabolically active areas, but with poor
anatomical definition.
Lymph Nodes
The risk of inguinal nodal involvement is low if
the primary is small [91], but approaches 20% in
cT3 or T4 cancers [92]. It should be borne in
mind that[50% of involved lymph nodes will
measure\5 mm. Fine needle aspirate cytology
(FNAC) of groin nodes can also be helpful.
Sentinel lymph node biopsy (SLNB) can
reveal the micrometastatic spread of disease in
normal sized lymph nodes, and hence may be
more accurate than conventional diagnostic
imaging with MRI, CT and PET/CT, but it
remains to be validated. A review of five small
published series (83 patients) evaluated SLNB in
normal-sized inguinal nodes in SCCA [93].
Nodal metastases were found in 7–42% of
cases, and no serious complications were
reported. A different review showed more
favourable results and identified inguinal
metastases in 13/63 patients (20.6%) with no
false-negative nodes [94]. However, we are not
yet in a position to stratify treatment according
to macroscopic nodal involvement, microscopic
involvement or the presence of a few isolated
cells found on SLNB.
Prior to the use of intensity-modulated
radiotherapy (IMRT) (which has been shown
to reduce acute toxicity), there was a rationale
for SLNB to spare formal inguinal irradiation,
thereby reducing skin morbidity and damage to
the femoral heads. The precision of IMRT means
it is possible to contour these areas as organs at
risk (OARs) and spare them. The risk of
metachronous inguinal node metastasis in
patients treated with prophylactic groin
radiation appears low (4%) [61]. The most
useful role of SLNB lies in identifying nodes in
patients with locoregional recurrence after CRT
so as to decide whether radical inguinal
dissection is required at the time of salvage
Table 5 Recommended investigations/staging policy for SCC of the anus
T1N0T1N0 T1N1T1N1 T2N0T2
N0
T2N1T2N1 T3N0T3N0 T3N1T3N1 T4T4
FBC, E?U, LFTs Yes Yes Yes Yes Yes Yes Yes
SCCAg
NR (1–150 ng/dl)
Yes Yes Yes Yes Yes Yes Yes
CT scan of whole
body
Yes Yes Yes Yes Yes Yes Yes
Ultrasound Sometimes Sometimes No No No No No
MRI Yes Yes Yes Yes Yes Yes Yes
Diffusion-weighted
MRI




Yes Yes Yes Yes Yes Yes
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surgery. There are also concerns that SLNB
could delay the start of CRT if healing in the
inguinal region is prolonged and prejudice its
effectiveness. In one study of SLNB, 24% of





The Radiation Therapy Oncology Group
RTOG-8704 trial explored the role of MMC in
addition to 5-FU in CRT. The protocol used a
median RT dose of 48 Gy and a potential boost
of 9 Gy for biopsy-confirmed residual disease.
The results demonstrated the superiority of
MMC/5-FU (2 courses of MMC at a dose of
10 mg/m2) over 5-FU alone when combined
with radiotherapy [9].
The US Intergroup RTOG 98-11 phase III trial
[12] randomly assigned 682 patients (limited to
anal canal tumors) to either induction 5-FU and
cisplatin for 2 cycles prior to concurrent
chemoradiation with 5-FU and cisplatin or the
standard arm of concurrent chemoradiation
with MMC/5-FU. The induction arm failed to
improve the primary endpoint of DFS, or
locoregional control, distant relapse or overall
survival (OS). The risk of a colostomy was
significantly higher in the cisplatin arm
compared with the mitomycin arm (19% vs
10%; p = 0.02). Haematological toxicity was
worse with mitomycin. In a subsequent report
of the RTOG98-11, the updated results [4]
actually showed an advantage in 5-year DFS
for 5-FU/MMC over induction cisplatin and
CRT with 5-FU/cisplatin.
In ACT II, using a 292 factorial design [6],
patients received 5-FU (1000 mg/m2/day on
days 1–4, 29–32) and radiotherapy (50.4 Gy in
28 daily fractions), and were randomised to
receive a single dose of MMC (12 mg/m2, day 1)
or cisplatin (60 mg/m2 on days 1, 29). There was
a second randomization between two further
courses of chemotherapy as consolidation after
CRT (5-FU/cisplatin) or no consolidation. In
ACT II, the efficacy of adding cisplatin was not
significantly different to that of adding MMC to
CRT in terms of achieving cCR, reducing
tumour relapse or cancer-specific deaths,
although haematological toxicity (but not
overall toxicity) was higher. Given the
superiority of 5-FU/MMC over 5-FU/cisplatin
in RTOG98-11 and the nonsignificant excess of
second malignancies in ACT II in the groups
receiving cisplatin compared to MMC (6 vs 14)
or the cisplatin arm in ACT II, 5-FU and MMC
(12 mg/m2 day 1 with a maximum
recommended dose of 20 mg) with
concomitant RT remain the standard CRT
recommended in the UK.
Optimising Radiotherapy
In the past two decades, trials have refined
radiotherapy techniques and proved the
efficacy of relatively low total radiation doses.
IMRT is considered the current standard.
However, the optimal schedules, target
volumes and radiation dose remain under
debate and continue to be examined in
clinical trials.
Field Size
Relapse can recur either at the primary tumour
site, in the regional lymph nodes, or at distant
sites. Evidence for the optimal RT dose and
fractionation is limited by a lack of data
regarding the pattern of failure. No
randomised study has published detailed data
Oncol Ther (2016) 4:135–172 151
describing the topography and sites of local
failure (within, marginal to, or outside of the
radiotherapy field). Preliminary data from the
ACT II trial suggest the majority of locoregional
failures occur in-field [96] and hence can be
attributed to an insufficient radiation dose or
intrinsic radioresistance rather than inadequate
clinical target volumes.
The ACCORD-03 phase III trial [5] compared
45 Gy in 25 daily fractions plus a 15 Gy boost
after a gap of 3 weeks with a higher boost dose
of 20–25 Gy (i.e. 65–70 Gy total dose), but
found no benefit in CFS at doses above 59 Gy,
and the optimal boost dose remains undefined.
Radiation Dose
Higher radiation doses using IMRT and with no
extension in the overall treatment time (OTT)
are proposed to improve results.
Brachytherapy can also boost a small volume
(usually the primary tumour), limiting or
sparing the adjacent normal tissues. Delivery
of a high-dose ‘‘boost’’ to the primary-tumour
area is feasible in selected patients, especially
those with more locally advanced disease (T3/
T4) where dose escalation may be of benefit
[97]. The technique demands skill and operator
experience, and a poor dose distribution risks
radionecrosis.
Technological advances such as IMRT,
rotational IMRT, image-guided radiotherapy
(IGRT) using cone-beam CT (CBCT), and
stereotactic techniques allow smaller margins
and highly conformal plans, resulting in
decreased radiation doses to the organs at risk
(OARs) and ensuring a shorter OTT. A
prospective phase II study conducted by the
Radiation Therapy Oncology Group (RTOG)
suggested that a reduction in acute toxicity
can be obtained with use of these techniques
compared with 2D or 3D techniques [98].
Hence, IMRT is the treatment of choice and is
being consistently delivered in the UK
according to a newly defined and developing
protocol. This is the rationale of the current
Plato trial that is funded to start in the UK in
2016.
Optimising Chemotherapy?
Jean Papillon originally said in 1987 that ‘‘The
use of chemotherapy during the first days of
irradiation is advisable in all cases to reinforce
the efficacy of treatment and increase the
chance of anal preservation.’’
Fluoropyrimidines
Continuous radiosensitisation (i.e. a prolonged
venous infusion) during the entire CRT
schedule has rarely been investigated in SCCA
[99, 100]. The oral fluoropyrimidine prodrug
capecitabine has been examined in the Extra
phase I/II trial [101] because its stepwise
conversion to 5-FU within the tumour by
thymidine phosphorylase theoretically offers a
potential therapeutic advantage over
intravenous 5-FU alone. Several other
investigators have confirmed that capecitabine
at a dose of 825 mg/m2 b.i.d. orally is tolerable
and appears effective [102–104]. A retrospective
comparison of capecitabine and infusional 5-FU
suggested capecitabine may even be more
effective [105].
MMC
The central role of MMC in SCCA therapy is
well accepted, yet the dose is still not
standardised, and optimal doses are unknown.
The RTOG-8704 trial used a MMC dose of
10 mg/m2 in weeks 1 and 5 [9]. In contrast,
European trials [6, 10, 11] used a single dose on
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day 1 of MMC at 12 mg/m2 (capped at a 20 mg
total dose in the ACT II study). Although MMC
has a rapid systemic elimination, it may persist
in hypoxic cells as a radiosensitiser for long
periods of time. It has a recognised biphasic
pattern of haematological toxicity. Hence, it is
not clear whether a second dose of MMC on day
29 adds to the efficacy of CRT or not, although
it has increased toxicity [9].
Cisplatin
Various cisplatin doses have been explored in
phase II [106, 107] and different retrospective
studies of CRT [108–111] between 60 and
80 mg/m2 on days 1 and 29, without
observing an obvious advantage to the higher
dose. In contrast to clinical studies in cervical
cancer, cisplatin has only been explored in a
weekly schedule in a single phase II study [100].
The EORTC 22011-40014 study randomised a
control arm of 5-FU and MMC in combination
with radiation versus MMC and cisplatin
concurrent with radiation using 25 mg/m2 per
week, with a total of 175/mg/m2 [100]. With a
median follow-up of 2 years, the 1-year
event-free survival was 74.4% vs 89.2%,
respectively, for the novel arm. The schedule
was not explored further in a planned phase III
design.
A phase II trial at the M.D. Anderson Cancer
Center examined the combination of
capecitabine and oxaliplatin with radiotherapy
[112]. Preliminary results show encouraging
response rates of 91–100% and a CFS of 100%.
Neoadjuvant or Induction Chemotherapy
The design of the Intergroup trial RTOG-9811
was based on the results of a successful phase II
trial [113]. Induction chemotherapy resulted in
8 CR and 21 PR in the 44 evaluable patients.
Only a single patient progressed. Following CRT
(which included a mandated 3-week gap) there
was a CCR rate of 82%. Overall, 16 patients had
persistent (n = 8) or subsequent locally
recurrent (n = 8) disease [113].
These encouraging results led to the
development of the RTOG9811 trial, which
used the induction regimen as the
experimental arm but did not use mitomycin
(as an additional potentially non-cross-resistant
component)—it was replaced by cisplatin—
making a total of 4 courses of 5-FU/cisplatin
[12]. This different novel arm was compared
with the standard 5-FU/MMC CRT, but the
CALGB study may have raised the acceptance
that a gap was not disadvantageous and could
be an acceptable treatment strategy.
Induction chemotherapy (ICT) using
cisplatin failed to improve OS, DFS,
locoregional control and distant relapse when
compared to the standard arm. Results after a
median follow-up of 2.51 years showed that the
3- and 5-year DFS rates were 67% and 61%,
respectively, in the MMC arm, versus 61% and
54% for the cisplatin arm. The 3- and 5-year OS
rates, at 84% and 75% for the MMC arm
compared to 76% and 70%, respectively, for
the cisplatin arm, were not significantly
different (p = 0.1) [12]. Interestingly, the
results for the CALGB trial parallel those in
the RTOG 9811 trial, but in the RTOG 9811
trial, only 26% of the patients had tumours
greater than 5 cm, and 26% had positive nodes.
In contrast, the CALGB trial restricted the
eligibility to stage cT3/T4 or lymph node
involvement (cN2/N3) [113].
Finally, the ACCORD-03 phase III trial [5]
randomised 307 patients in a factorial 292 trial
design between 2 cycles of induction
chemotherapy (ICT) with 5-FU and cisplatin
and secondly a radiation dose escalation. With a
mean follow-up of 50 months, the results did
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not show any benefit of ICT compared to
standard treatment [5], probably because a
21-day interval was mandated between the




The addition of consolidation chemotherapy
after CRT is intended to increase efficacy. An
early pilot of this strategy in which three
cytotoxics were added to radiotherapy in a
CRT schedule and also administered as
consolidation proved too toxic to consider for
a phase III trial [114]. Despite these results, a
two-drug maintenance chemotherapy schedule
using 5-FU and cisplatin was adopted in the
ACT II phase III trial on the basis of this pilot
study, i.e. 2 courses of 5-FU 750 mg/m2 for
4 days and cisplatin 60 mg/m2 on days 71 and
98 (i.e. 11 and 14 weeks from start of treatment)
in a second randomization as consolidation. In
the ACT II trial there was no significant benefit
for consolidation/maintenance chemotherapy
[6] in terms of achieving cCR or reducing
tumour relapse or cancer-specific deaths
compared to the standard arm using MMC/CRT.
The Role of Surgery, Treatment of Small
Cancers and Postoperative Adjuvant
Treatment
Smaller lesions (\2 cm in diameter) involving
the anal margin can be treated by primary
surgery with a local excision provided the
surgeon considers that the margins ([5 mm)
can be obtained without compromising
sphincter function (IVC). This practice is often
discouraged because delivery of CRT to residual
disease after excision biopsy with positive
margins is often delayed and/or compromised
by a poorly healing wound cavity. However,
local surgical excision is associated with a high
risk of close or positive surgical margins, even in
small lesions (14/26 positive margins) [115].
Local excision is contraindicated for small
tumours in the anal canal.
A few retrospective studies have examined
local excision in anal margin tumours, but there
are no consistent data regarding appropriate
tumour characteristics or a safe excision margin
status, or how these features impact on
subsequent inguinal node recurrence.
Although more extensive and poorly
differentiated lesions have a greater risk of
being lymph node positive, staging of smaller
lesions is important to rule out the presence of
positive nodes, as this also is a contraindication
for local excision. Some consider that adverse
features associated with SCC skin cancers are
relevant. These features include tumour
diameter[2 cm, poorly differentiated
histology, depth of tumour invasion beyond
fat and perineural invasion [116], which
account for the majority of poor outcomes
and 70% of patients harbouring regional nodal
metastases. However, anogenital lesions were
specifically excluded from this analysis.
If a local excision has been performed,
simple advancement flaps, with or without
faecal diversion, may be used to close the
resulting defect, but adjuvant CRT to a dose of
30–36 Gy concurrent chemotherapy using
5-FU/MMC is often recommended, although
many European radiation oncologists tend to
use higher doses.
In the case of inadequate margins or R1
resection (found after a resection of ‘‘anal tags’’
or ‘‘haemorrhoids’’), re-excision is sometimes
feasible, but it is difficult for the surgeon to be
sure the increased depth of tissue is taken from
the correct place. Piecemeal resections render
assessment of resection margins in the
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specimen impossible and should not be
performed.
However, it is recommended that all patients
who have undergone a local resection,
irrespective of the resection margin, should be
discussed by an appropriate multidisciplinary
team (MDT). Nonspecialist surgeons who are
less familiar with SCCA sometimes perform
local excision with a resulting positive margin,
and, in the absence of visible tumor, directing
the radiation field may be problematic for the
radiation oncologist.
Postoperative CRT is administered if the
pathologist is unsure of the completeness of
excision, or in cases with positive or narrow
margins. Some authors argue that smaller fields
can be treated, and that the total dose can be
lowered to 30 Gy for microscopic disease
[117, 118].
There are still some patients who undergo
initial abdominoperineal resection as definitive
treatment of their SCCA. This sometimes results
from a small poorly differentiated biopsy which
is not recognised as SCC histology and treated
as a low rectal cancer. Appropriate information
such as CDX2 staining should be considered by
the pathologist. There are also occasions, if the
patient has already received radical
radiotherapy to the pelvis, when an




There is debate regarding the safest time to
define lack of treatment response and persistent
local disease. Some have defined persistent
disease as the presence of residual carcinoma
up to 6 months following the completion of
CRT, and recurrent disease as regrowth of
tumour identified [6 months from the
completion of CRT. Guidelines for SCCA have
in the past recommended assessment of
response at 6–12 weeks. In early randomised
trials and one population study, a single
response assessment at 4–8 weeks after the
completion of CRT found that 10–60% of
patients fail to respond [9–11]. In ACT I,
radical surgery as salvage was intended for
patients with\50% response at EUA planned
for 6 weeks after completion of CRT. The trial
results suggested that 29/43 patients with an
inadequate clinical response (65%) actually
proceeded to radical surgery [10]. Similarly, in
the EORTC trial, radical surgery as salvage was
intended for patients with progression or no
response [11], and this appears to have been
performed in 5 patients in the RT-alone arm but
in no patients in the CRT arm. In addition,
surgery seems to have been performed in a
further 15 patients who achieved either partial
or complete remission.
In the RTOG 8704 trial, a biopsy was
mandated for patients if residual disease was
observed clinically 4–6 weeks after completion
of CRT to assess pathological response [9]. A
positive biopsy dictated an additional salvage
CRT regimen (using 9 Gy in 5 fractions)
concurrently with 5-FU and cisplatin 100 mg/
m2, which 25 patients received. If a further
repeat biopsy 6 weeks after the salvage CRT was
still positive, patients proceeded to APR. The
ACCORD-03 trial recommended APR in
nonresponders, which was performed in 7
patients [5], so patients with residual tumour
proceeded to salvage.
In practice, persistent ulceration can raise
suspicion of ongoing nonresponding disease,
though definitive histology is usually required
before submitting the patient to APR [119].
Positron emission tomography at 1 month has
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also been advocated to assess clinical response
[120].
Nowadays, most wait for longer periods to
allow assessment of regression. In the ACT II
trial, complete clinical response (cCR)—i.e.
complete absence of tumour and clinically
node negative—was assessed by DRE or
imaging at 11 and 18 weeks with a mandated
CT at 26 weeks after the start of CRT. At week
11, 66% of patients achieved cCR with MMC
and 56% with cisplatin, compared to 75% and
76% at 18 weeks and 83% and 84% at
26 weeks, respectively [6, 121]. So, whilst we
would advise careful monitoring of the
inguinal region and primary tumour after
completion of CRT to facilitate timely
surgical salvage for progression, it appears
safe to observe a resolving tumour up to
26 weeks following the start of CRT.
Follow-up Surveillance
Following radical CRT, regression is recognised
to be slow, and may take up to 6 months. The
guidelines of the American Society of Colon and
Rectal Surgeons (ASCRS) suggest that
surveillance should be undertaken every
3–6 months for the first 24 months. Our
current protocol is that follow-up surveillance
should start 12 weeks after the completion of
CRT and continue for at least 3–5 years. The
patient is reviewed every 3–6 months for a
period of 2 years, and subsequently 6- to
12-monthly until 5 years. We perform MRI at
3 and 6 months for low-risk and at 12, 18 and
24 months for high-risk patients.
Recommendations for follow-up include
digital rectal examination (DRE), anoscopy,
inguinal lymph node palpation, and
thoracoabdominal CT scan. DRE may fail to
detect some locoregional recurrences, and the
use and frequency of pelvic MRI surveillance
should reflect the perceived risk of local
recurrence.
Retrospective studies suggest that 20–25% of
cases develop local recurrence/regrowth within
the first 3 years. Patients tend to relapse
locoregionally rather than at distant sites, but
only 7% of all locoregional relapses occur
beyond 3 years [96]. Hence, there is an
argument for performing pelvic MRI
surveillance to detect potentially salvageable
pelvic failure.
The ideal investigations and the optimal
frequency and duration of follow-up after CRT
remain a matter of debate. Well-designed,
prospective, multi-institutional, randomised
studies are needed to define an evidence-based
consensus for follow-up. The supportive
argument focuses on the early identification of
locoregional recurrence amenable to salvage
surgery, but it also allows the clinician to
manage late effects of treatment on urinary,
bowel and sexual function, to provide
psychological support, and to ensure that the
patient maintains positive changes in diet and
lifestyle—in particular smoking cessation.
Ongoing regular contact with health care
professionals (HCPs) may also improve the
detection and management of serious
comorbidities.
The Role of Surgery
Salvage Surgery
Isolated locoregional relapse from SCCA can be
salvaged by a radical abdominoperineal
resection (APR), but sometimes it is necessary
to consider a posterior or total pelvic
exenteration. An APR is extended to
encompass adjacent viscera (e.g. the vagina in
women) and irradiated soft tissue of the
perianal area, perineum, and buttocks, which
is a distinct operation from that performed for
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low rectal adenocarcinomas. There is often a
need for plastic surgery to reconstruct the
perineal defect. Outcomes vary, but a local
pelvic disease control rate of approximately
60% can be achieved if negative surgical
margins are achieved with an associated 5-year
survival rate of about 40–50% [60, 122]. In the
largest single series of APR for SCCA, major
prognostic factors for survival and recurrence
were again T status and involved margin. This
study achieved a 5-year overall survival of 60%
[123]. Other previous studies have identified
positive surgical margins, nodal involvement
and perineural/lymphovascular invasion as
factors associated with survival [124]. In a
small study from Swansea, 11/96 (12%)
required salvage surgery following CRT, five of
whom were stage T4 at presentation. Six
patients had failed to respond to CRT, and five
presented with recurrence at a median of 10
(10–36) months [125].
Since most locoregional recurrence occurs
within the first 3 years following CRT [96], some
surgical groups have adopted a proactive
approach with sequential surveillance CT or
pelvic MRI to detect early relapse, taking the
view that there may be a limited window of
opportunity to resect a local disease relapse. In
the Manchester series of 254 patients treated
with curative intent, 73/99 relapses (74%)
underwent salvage APR [60]. The
corresponding rate in the contemporaneous
UKCCCR ACT I trial was only 56% [10].
Late Effects
The majority of patients with SCCA are cured by
CRT, and surgery can salvage at least 50% of
local relapses. Hence, if patients survive long
term, it is even more important to minimise late
effects, which are infrequently reported and
poorly recorded in phase III trials. There is a
wide spectrum of effects, from minor persistent
symptoms to life-threatening complications,
but there is still no widely accepted
classification for describing late morbidity of
radiation. The WHO and RTOG/ECOG systems,
used in the EORTC, ACT I and RTOG-8704
trials, were not specifically designed to capture
radiation-induced morbidity.
The ACT I trial defined any toxicity
occurring or persisting more than 6 months
after completing initial radiotherapy as late
morbidity. Toxicity was not scored or
quantified [3] but simply described, and was
more common in the subgroup who received
boost by implant (14%) compared with an EBRT
boost (6%; p = 0.003), although post-treatment
biopsies for suspicion of residual disease might
have contributed in some to nonhealing and
ulceration. The ACT II trial collected regular
descriptive reports of the presence or not of a
range of late effects (bowel, urinary and sexual)
which were considered by the investigator to be
severe but were not formally graded according
to the RTOG scale. However, many patients
have severe G3/G4 late effects [126], and up to
20% historically required a colostomy for these
adverse late effects alone [127].
Long-term colostomy rates vary from 15% to
36% in the randomised trials [10, 11] and
population studies [59], of which
approximately 10% are fashioned initially for
symptom control. Most of these are never
reversed. In addition, 10–15% of colostomies
are required to deal with the consequences of
treatment [3, 12]. In the RTOG-9811 trial, the
rate of severe long-term toxic effects was similar
in both arms, 11% vs. 10%, but only 5%
required a colostomy for treatment-related
problems.
Hence, nurse-led clinics promoting
survivorship in patients who have received
pelvic radiotherapy are gaining support
[128, 129]. These identify late effects, enabling
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therapeutic interventions and counselling to
reduce the psychosocial and physical impacts of
such symptoms. There are also reports detailing
the effectiveness of pelvic floor exercises and/or
biofeedback training in patients who experience
faecal urgency and incontinence.
Quality of Life
Effects of treatment on long-term quality of
life (QOL) in patients with SCCA based on
data within the published randomised trials
have not been published, partly due to the
absence of an available validated
questionnaire specific to SCCA at the time of
trial design. Preliminary data from ACT I [130]
were presented in an abstract only. In the
ACCORD-03 study, an early assessment at
2 months after completion of CRT did not
show that NACT and high-dose radiotherapy,
either alone or in combination, had a negative
impact on quality of life [131]. In fact, QOL
appeared to be better than the QOL defined at
entry prior to CRT.
Retrospective analysis of long-term QOL
suggests there is a high rate of faecal
incontinence [7, 132] sexual problems in both
males and females as well as financial difficulties,
even5 years later.However, some studies seemto
demonstrate that QOL is satisfactory to patients
despite an objective impairment of sphincter
function [133, 134]. There has been a recent
systematic review on this topic [135]. Currently,
a specific EORTC anal cancer module is being
developed to replace several other modules that
are frequently used—EORTC QLQ-C30
and-CR29 (colorectal cancer), EORTC
QLQ-PRT23 (for radiation proctitis) and EORTC
QLQ-PR25 (for prostate cancer)—to include all
QOL issues relevant and specific to anal cancer,




Carcinoma of the anus rarely spreads outside
the pelvis unless the primary tumour is
unresponsive to chemoradiation or local
failure is observed. Distant disease at
presentation is reported in less than 5% of
cases, and usually involves para-aortic nodes,
lung, liver or bone.
Although single-agent carboplatin has been
examined, the combination of 5-FU and
cisplatin remains the most commonly used
palliative regimen, and it is the only regimen
recommended in the NCCN guidelines [14].
Response rates of 20–60% are reported when
this regimen is used as the first-line therapy, but
such rates are rarely sustained. Few reports have
included more than a handful of patients. There
is currently an international randomised phase
II trial comparing the standard of 5-FU/cisplatin
against carboplatin/taxol in progress under the
aegis of the IRCF (Interract NCT). Clinical
decisions such as whether to continue therapy
until resistance or toxicity is reached as opposed
to stopping treatment after a defined number of
chemotherapy cycles in metastatic SCCA
remain unanswered. Randomised trials
incorporating EGFR inhibitors might be a




Technical advances in radiation oncology such
as IMRT allow better precision with adequate
doses of radiotherapy to the tumour while
sparing sensitive normal surrounding
structures such as perineal skin, the external
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genitalia, the bony confines of the pelvis
(sacrum and pubis), the femoral head and
neck, the bladder and the small bowel. IMRT
also offers the potential for dose escalation of
the radiotherapy. IMRT appears most useful in
tumour sites with a marked dose–response curve
(such as prostate cancer and head and neck
cancer) or that are close to critical organs.
The ACT II trial used low doses to treat the
nodes electively in the first phase of treatment
(30.6 Gy in 17 daily fractions), which
successfully prevented disease at these sites [6].
There is further retrospective support for the
efficacy of a low-dose (36 Gy) elective nodal
irradiation [136]. The differential doses required
for elective nodal irradiation and the gross
primary/nodal tumour favour the use of IMRT.
The shapes of the lymph node targets in the
pelvis are predominantly concave, and it is
difficult to spare normal tissue using 3D-CRT
techniques. With IMRT or rotational IMRT
using highly modulated dose fluence from
multiple directions, we can limit the high-dose
volume outside the treatment target, reducing
the dose to OARs and thereby modifying acute
and late toxicity.
Sparing the anal canal is difficult, and the
maximal dose to the sphincters may predict the
risk of complications. There is limited evidence
regarding long-term function, but the
maximum dose to the anal canal has been
recommended by some to be only 55 Gy [137].
A multicentre study of IMRT [138] reduced
acute grade 3 toxicity and still maintained good
LC. Further data from this study showed that
the volume of bowel receiving 30 Gy V(30)
correlated with acute gastrointestinal (GI)
toxicity in chemo IMRT-treated SCCA patients.
Similarly, IMRT treated elective pelvic regions
and inguinal nodes (to 45 Gy) but reduced the
volume of pelvic bone marrow receiving 15 and
20 Gy (PBM-V15 and PBM-V20), which appears
to affect the absolute nadir neutrophil count
(ANC) [139]. This sparing of normal tissues may
allow improved compliance and maintains a
short OTT. Late morbidity is likely to be
reduced, albeit at the price of more second




EGFR is overexpressed in up to 90% of SCCAs
[140–142], and EGFR, K-RAS or BRAF mutations
are rarely identified [141, 143–146], although
one study showed that PIK3CA was mutated in
22% of cases [145]. Pre-clinical studies suggest
that inhibiting EGFR signalling slows cell
proliferation in vitro and in vivo and
promotes additive effects with radiotherapy
[147]. EGFR contributes to tumour
development and progression through
autocrine stimulation of cell proliferation. In
addition, radiation itself induces EGFR
activation, which contributes—at least in
part—to the mechanism of accelerated
proliferation, and can be expected to increase
the capacity for tumour DNA damage repair.
Overexpression of epidermal growth factor
receptor (EGFR) has been linked to
radioresistance [148, 149].
A landmark phase III study in patients with
locally advanced squamous cell head and neck
cancer [150] showed that cetuximab (a
recombinant, chimeric monoclonal antibody
directed against the epidermal growth factor
receptor) in combination with radical
radiotherapy significantly improved overall
survival compared to radiation alone. Hence,
there may be a therapeutic role for agents
causing EGFR inhibition in SCCA either as a
single agent with radiation or in combination
with standard CRT.
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In SCCA, several small studies have
evaluated the combination of 5-FU, cisplatin
and cetuximab with radiation. In a Brazilian
study [151], 23 patients were enrolled, but—
despite a response rate of 95%—the study was
closed early due to toxicity, including 6 (26%)
episodes of thrombosis and embolism, 12 (52%)
cases of severe grade 3-4 radiation dermatitis
and 10 (44%) cases of grade 3-4 diarrhoea.
The ACCORD 16 phase trial also evaluated
cetuximab in combination with CRT using
5-FU, cisplatin and 45 Gy of RT, but it too
closed early because the authors concluded that
the toxicity was unacceptable [152], with
serious adverse events seen in 14 out of 16
patients (i.e. grade 3/4 acute toxic effects in 88%
of patients), although there were no toxic
deaths.
Two other small phase II studies in the USA
(ECOG 3205 for immunocompetent patients;
AMC045 for HIV-positive patients) showed
more reasonable clinical outcomes for patients
treated with the combination of cetuximab
with 5-FU and cisplatin concurrently with
radiation. These studies included 45 and 28
patients, respectively, and reported 2-year OS
rates of 89% and 93% [153].
The ECOG 3205 phase II trial had two
cohorts: cohort A included induction
chemotherapy with cisplatin and
5-fluorouracil followed by CRT with
cetuximab, cisplatin, and 5-fluorouracil to a
total radiation dose of 54 Gy. Arm B had the
same CRT doses and schedule as arm A but
without the induction chemotherapy. Arm A
closed after the accrual of 28 patients and the
induction arm was discontinued. For the 28
subjects in arm A, preliminary results showed
that the colostomy rate was 14%, the 2-year PFS
was 92%, and the 2-year OS was 93%. The
primary endpoint of failure at 3 years was not
reached. Results for arm B are not yet available.
The AIDS Malignancy Consortium treated
HIV-positive patients in a phase II trial
(AMC045) using CRT with cetuximab,
cisplatin, and 5-fluorouracil, similar to ECOG
3205. The 2-year local/regional failure rate was
7%, 2-year OS 89%, and 2-year colostomy rate
7%. It is unclear why neither ECOG 3205 nor
AMC045 reported the unwelcome and unusual
toxicity seen in ACCORD16 and the phase I
study [151, 152], although it may reflect
differences in the radiation dose, the field size
or the patient population.
Finally, a recent phase I study employed
IMRT and combined cetuximab with 5-FU/
MMC-based CRT using a simultaneous
integrated boost (SIB) administering 57.5/54.0/
48.6 Gy in 27 fractions to primary tumor/lymph
node metastases/adjuvant lymph node regions,
respectively [154]. Toxicity was acceptable, and
3 months following completion of CRT, 10/11
patients (91%) achieved local complete
remission (CR). The MTDs for the agents
combined with cetuximab were determined as
5-FU 800 mg/m2 on RT days 1–4 and 29–32 and
MMC 8 mg/m2 on days 1 and 29. Hence, there
is insufficient evidence to recommend the use
of cetuximab in concurrent CRT in SCCA (see
Table 6).
Two further phase II studies (NCT01843452
and NCT01285778) are currently evaluating the
benefit of the addition of panitumumab to CRT
with capecitabine and mitomycin C. The Vital
trial (NCT01285778) has finished recruiting
patients.
PI3K/AKT/mTOR Pathway
The phosphatidylinositol 3-kinase pathway
offers a further potential therapeutic target for
SCCA because this pathway appears associated
with clinical radioresistance in HPV-related
SCCHN [148]. (PI3K)/AKT is hyperactivated in
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many squamous cell cancers, particularly
HPV-related head and neck cancers. Mutations
in PIK3CA, Akt1 and FBXW7 are frequent, along
with PTEN loss, suggesting a potential for
targeting the PI3K pathway. Mutations in
PIK3CA were reported in 13/84 patients with
SCCA (16%) and KRAS mutations in 4/84 (5%),
respectively [142], and a study of 128 patients
with SCCA showed that 66% had cellular
accumulation of phosphorylated AKT. There
was a significant correlation between HPV
infection and activated AKT [155] and high
frequency of copy number gain at PIK3CA
(47%). There are now some agents such as the
Akt inhibitor afuresertib in development that
are able to target this signalling pathway and
could be explored as combinations with
chemotherapy and radiotherapy.
Immunotherapy
The importance of functional immune
surveillance in controlling cancer is well
recognised. Studies in SCCA show a
correlation between tumor-infiltrating
lymphocytes (TILs) in cancer tissue and a
favourable prognosis. In particular, the
presence of CD8? T cells and the ratio of
CD8? effector T cells to FoxP3? regulatory T
cells seem to be correlated with improved
prognosis and long-term survival in many
solid tumors. SCCA is no exception.
Tumours upregulate inhibitory molecules
such as programmed death receptor-1 (PD-1)
and its ligands PD-L1 and PD-L2, which
suppress the host antitumour immune
response and antagonise any immunogenic
effects HPV or CRT can raise. The normal
function of PD-1, expressed on the cell surface
of activated T cells, is to downmodulate
unwanted or excessive immune responses,
including autoimmune reactions. If the PD-1
ligand from the cancer cells binds to its
receptors on activated T cells, then the T cell
is unable to recognise or produce any
immunological effects on cancer cells or
indeed any antigens [156]. This activation
facilitates cancer progression. Many cancer
cells, including SCCA, express the PD-1 ligand.
A recent small study reported the presence or
absence of PD-L1 expression in 41 patients with
SCCA. PD-L1 expression was seen in 62% of
cases with late/unknown-stage disease and 33%
of cases with early-stage disease [157].
Interestingly, in non-small-cell lung cancer,
current smokers are significantly more likely to
Table 6 Preliminary and full results of phase I/phase II studies integrating cetuximab into CRT regimens
Trial No of patients IMRT Regimen Toxicity Efﬁcacy
















Lowa 93% OS at 2 years
Leon et al. [154] 13 Yes 5-FU/MMC
?RT ? cetuximab
Lowa 73% CR at 3 months
a Our subjective interpretation of the toxicity in terms of being able to deliver the schedule within a randomised trial
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express the PD-1 receptor than nonsmokers.
Immunotherapy drugs which block the binding
of thePD-1 ligand to its receptor, allowactivatedT
cells to recognise and infiltrate cancer cells. The
precise threshold for meaningful PD-L1 positivity
with immunohistochemistry (IHC) assays to
predict response to such agents remains
controversial. Pembrolizumab is a humanised
monoclonal antibody against PD-1 which blocks
PD-1receptorsbinding thecancercellsPD-L1.The
KEYNOTE trials of pembrolizumab used a high
breakpoint (50%) for PD-L1 expression. Proof of
principle of activity was achieved in a study
presented at ESMO 2015 which included 25
heavily pretreated patients with PD-L1-positive
advanced SCCA; in that study, pembrolizumab
demonstrated amanageable safety profilewith an
overall response rate of 5/25 (20%) and
stable disease in a further 10 patients (40%)
[158]. Additionally, there are now many studies
suggesting synergistic effects on LC and abscopal
effects on distant tumour control when radiation
therapy is combined with immunotherapy
[159, 160]. This has led to the hypothesis that
combining radiation with checkpoint blockade
immunotherapy will increase radiosensitisation,
improve local tumour control and prevent the
development of overt metastatic disease by
reactivating antitumour T cells which have
become tolerant.
Asmentioned above, HPV plays an important
role in the development and progression of
SCCA, the majority being associated with
HPV-16 and HPV-18. Some have suggested that
the favourable outcomes from HPV? tumours
compared to HPV- tumours are because HPV
antigens may elicit a host immune response
directed against the cancer cells. T-cellmigration
into tumourmassesmay be critical to the process
of immunologically induced tumour regression.
Reports suggesting improved outcomes in SCCA
tumours with massive TILs [161] support this
hypothesis. If a clear biological relevance of the
TIL response can be shown in SCCA, this would
support trials of immunotherapy (targeting
immune checkpoints via anti CTLA4/PD1/PDL1
agents) in this tumour type, either in the
metastatic setting or potentially combined with
chemoradiotherapy, either in the concurrent or
(neo)adjuvant setting [162].
An alternative strategy is the use of
autologous TILs targeting HPV. White blood
cells are harvested from the patient’s tumour,
grown in the laboratory in large numbers, and
then injected back into the patient. Promising
results have been observed in other SCCs such
as cervical cancer and head and neck cancer.
There is a currently open phase II trial
(NCT01585428) that is studying autologous
TILs and high-dose interleukin-2 for
HPV-associated cancers, including SCCA
following a lymphodepletion.
SCCA cells infected by HPV also have the
tumour-associated antigen HPV E7. The viral
gene products E6 and E7 are responsible for the
oncogenic potential by inhibiting normal cell
cycle checkpoints and inducing cell division,
which can be targeted immunologically. Normal
antiviral immune defence systems do not come
into play because of the HPV16-E6 and E7
oncoproteins [163]. E6 lowers the levels of
E-cadherin on the surface of keratinocytes,
which in turn (because of modified adhesion
properties) aids the survival of the virus by
limiting the presentation of viral antigens to
the immune system [164]. A further phase I/II
study (NCT02280811) uses T-cell receptor
immunotherapy targeting HPV-16 E6. This
study is similar to the above except that the
cells are genetically modified with a retrovirus to
attack tumour cells.
ADXS11-001 is a live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete a
HPV-16 E7 fusion protein targeting
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HPV-transformed cells. This vaccine aims to
elicit an immune response against human
papillomavirus (HPV) oncoprotein E7 [165]. In
preclinical studies, ADXS-HPV generates T-cells
directed against a cancer antigen neutralise
Tregs and myeloid-derived suppressor cells
(MDSCs), which protect the tumour
microenvironment from immunologic
recognition and contribute to tumour growth.
ADXS11-001 is currently being evaluated for
treatment of cervical cancer and SCCA in phase
I/II clinical trials. A current phase II trial in
SCCA is evaluating ADXS11-001 in
combination with concurrent 5-FU,
mitomycin and IMRT (NCT01671488).
ADXS11-001 causes antigen-presenting cells to
be stimulated, and thereby facilitates the
attachment of immune cells to SCCA cells
expressing HPV E7. Activity has already been
demonstrated in recurrent/refractory SCC of the
cervix [166, 167], where a phase III trial is
underway.
Finally, CHK1 is a multifunctional kinase
crucial for checkpoint control, DNA repair, cell
cycle replication, andproliferation. By inhibiting
CHK1, tumour DNA is damaged and unable to
pass through mitosis. The CHK 1/2 inhibitor
(LY2606368) is being investigated as a single
agent in patients with metastatic SCCA [168].
CONCLUSION
Future prevention of SCCA is feasible, but is
likely to rely on effective vaccination and
screening measures. In established SCCA,
clinical staging using the tumour/node/
metastasis (TNM) categorisation does not
predict response to treatment and outcomes
for the individual with confidence. We have a
standard regimen of 5-FU/MMC CRT for all
patients. Yet, early cT1 tumours with a
locoregional control of[90% are probably
overtreated with current regimens, while cT3/
T4 lesions have a 3-year DFS of only 35–68%
and thus might benefit from more intensive
treatment and a proactive approach to surgical
salvage. Some patients experience only limited
benefit from CRT and are still left with
significant late morbidity. After decades of
research, we have not found robust markers
for radioresponsiveness that can be applied in
the clinic. The response to CRT is
heterogeneous and may reflect the tumour
environment and the immunological capacity
more than innate radiosensitivity.
Current more-sophisticated risk assessment
techniques (using p16, SCCAg, PET/CT, TSIL,
PD-1 expression) may allow us to stratify SCCA
more accurately and help to tailor the intensity
of treatment to the individual. The increased
precision with IMRT can spare critical normal
tissues, may reduce acute toxicity and/or allow
dose escalation to be performed safely.
Integration of novel biological therapies with
conventional chemotherapies so far have not
improved outcomes. The most hopeful addition
to treatment lies with immune modulators and
the checkpoint inhibitors such as PD-1
inhibitors, which have shown spectacular early
promise.
However, it will be important to ensure these
novel treatments do not impact adversely on
acute toxicity and late function, which is likely to
have a knock-on effect on colostomy-free
survival. Both the effectiveness of treatment and
the risk of developing severe toxicity with radical
CRT depend on the genetic background of the
patient, the past and present lifestyle, the already
acquiredmorbidity as well as the size and stage of
the tumour, the intensity of chemotherapy and
the total dose of radiotherapy. Understanding the
molecular and immunological characteristics of
both the tumour and the whole patient are
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therefore going to be important in attempts to
identify predictive biomarkers and individualise
treatment.
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